Pan-European Study on Pancreatic Cancer Risk in Adults with Type 2 Diabetes Starting Exenatide or Other Glucose Lowering Drugs

What this Trial Is About

Researchers are conducting a large observational safety study called EXCEED to assess the risk of developing pancreatic cancer in adults with type 2 diabetes mellitus T2DM who started treatment with exenatide compared to those who started other glucose lowering drugs not including GLP-1 receptor agonists. This study uses retrospective data from multiple European countries collected from 2006 to 2023. Patients are matched by various factors to compare outcomes using an intention-to-treat approach. The study identifies two groups of patients those who initiated exenatide treatment and those who started other non-GLP-1 RA based glucose lowering drugs. Medication exposure is determined through prescription records or insurance claims available in eight data sources across seven countries. The follow-up period averages about 1.5 years or less, during which the occurrence of a primary diagnosis of pancreatic cancer is recorded and analyzed. Participants are not actively treated as part of the study but are observed through existing healthcare data. The main measurement is the incidence rate and hazard ratio of pancreatic cancer diagnosis during follow-up. Data includes medical histories, prescriptions, and diagnoses collected retrospectively. The study spans from 2024 to 2026 and aims to provide long-term safety information regarding exenatide use in T2DM patients.

A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs